AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17634259 — intervention group
Group type: COMPARATOR
Intervention: CHO (0.3 g x kg(‐1) carbohydrate)
Number of subjects: 7
Study 17634259 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO
Number of subjects: 7
Study 17634259 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 7
Study 16075773 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based intervention
Number of subjects: 66
Study 16075773 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-plus-telephone mediated intervention
Number of subjects: 66
Study 11437018 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment for depression
Number of subjects: 151
Study 11437018 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 151
Study 9510453 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of CPAP
Number of subjects: 88
Study 9510453 — intervention group
Group type: COMPARATOR
Intervention: Continuation of CPAP
Number of subjects: 88
Study 8290177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen
Number of subjects: 103
Study 8290177 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg conjugated equine estrogen
Number of subjects: 103
Study 8290177 — intervention group
Group type: COMPARATOR
Intervention: Cyclic medroxyprogesterone acetate (progestin) added to estrogen
Number of subjects: 103
Study 3678121 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic sampling shield
Number of subjects: 13
Study 3678121 — intervention group
Group type: COMPARATOR
Intervention: Control feeds
Number of subjects: 13
Study 30465382 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal AVF (Group B)
Number of subjects: 230
Study 30465382 — intervention group
Group type: COMPARATOR
Intervention: Distal AVF (Group A)
Number of subjects: 230
Study 28095544 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day sequential Q-switched Nd:YAG laser and 1565 nm non-ablative fractional laser (SST)
Number of subjects: 17
Study 28095544 — intervention group
Group type: COMPARATOR
Intervention: Fractional non-ablative laser (NAFL) treatment only
Number of subjects: 17
Study 24947625 — intervention group
Group type: EXPERIMENTAL
Intervention: LRYGB with closing of mesenteric defects using hernia clips
Number of subjects: 500
Study 24947625 — intervention group
Group type: COMPARATOR
Intervention: LRYGB without closing the mesenteric defects
Number of subjects: 500
Study 24034101 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of iliac vein after catheter-directed thrombolysis (CDT)
Number of subjects: 74
Study 24034101 — intervention group
Group type: COMPARATOR
Intervention: No stenting (control group)
Number of subjects: 74
Study 22047542 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFO)
Number of subjects: 400
Study 22047542 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 400
Study 19392908 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Cognitive Behavioral Therapy (E-CBT)
Number of subjects: 402
Study 19392908 — intervention group
Group type: COMPARATOR
Intervention: Extended Nicotine Replacement Therapy (E-NRT)
Number of subjects: 402
Study 19392908 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 402
Study 19392908 — intervention group
Group type: COMPARATOR
Intervention: E-CBT plus E-NRT (E-combined)
Number of subjects: 402
Study 17047492 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 340
Study 17047492 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz without nelfinavir
Number of subjects: 340
Study 12737857 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary fibre intake (highest quintile)
Number of subjects: 39562
Study 12737857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre from grains and cereals
Number of subjects: 39562
Study 12737857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre from fruits
Number of subjects: 39562
Study 12737857 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced and non-advanced adenoma
Number of subjects: 39562
Study 12737857 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal adenoma
Number of subjects: 39562
Study 11876893 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated drug-containing porcine-cornea (ofloxacin, acetyl cysteine, reduced glutathione)
Number of subjects: 55
Study 11876893 — intervention group
Group type: COMPARATOR
Intervention: Routine program
Number of subjects: 55
Study 9292758 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (six mugs daily)
Number of subjects: 65
Study 9292758 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water, caffeine, milk and sugar)
Number of subjects: 65
Study 8378047 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured materials (Vitrebond)
Number of subjects: 60
Study 8378047 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured materials (Prisma VLC Dycal)
Number of subjects: 60
Study 8378047 — intervention group
Group type: COMPARATOR
Intervention: Chemically cured materials (Ketac Fil)
Number of subjects: 60
Study 8378047 — intervention group
Group type: COMPARATOR
Intervention: Chemically cured materials (Dycal)
Number of subjects: 60
Study 6367413 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (0.2 mg/kg total by bolus and by 10-minute infusion)
Number of subjects: 16
Study 6367413 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline solution)
Number of subjects: 16
Study 31071658 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training for 6 weeks
Number of subjects: 50
Study 31071658 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 50
Study 29521039 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone Ahmed® valves
Number of subjects: 50
Study 29521039 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene Ahmed® valves
Number of subjects: 50
Study 29521039 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 27367585 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with 10 mg Lutein, 2 mg Zeaxanthin, and 10 mg Meso-zeaxanthin for 12 months
Number of subjects: 105
Study 27367585 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 105
Study 24440210 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of Ty21a vaccine with anti-helminthic treatment
Number of subjects: 252
Study 24440210 — intervention group
Group type: COMPARATOR
Intervention: Liquid formulation of Ty21a vaccine without anti-helminthic treatment
Number of subjects: 252
Study 24440210 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of Ty21a vaccine
Number of subjects: 252
Study 22158730 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet (>40% of energy from protein and 30% of energy from fat)
Number of subjects: 57
Study 22158730 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein (SP) diet (<15% of energy from protein and 30% of energy from fat)
Number of subjects: 57
Study 20345508 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 124
Study 20345508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 18046665 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16393283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 116
Study 16393283 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 116
Study 16393283 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin and albumin
Number of subjects: 116
Study 16393283 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 116
Study 14996676 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha2a, 180 microg/wk for 48 weeks plus standard-dose ribavirin (1000 or 1200 mg/d)
Number of subjects: 1311
Study 14996676 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon-alpha2a, 180 microg/wk for 24 weeks plus low-dose ribavirin (800 mg/d)
Number of subjects: 1311
Study 14996676 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon-alpha2a, 180 microg/wk for 48 weeks plus low-dose ribavirin (800 mg/d)
Number of subjects: 1311
Study 14996676 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon-alpha2a, 180 microg/wk for 24 weeks plus standard-dose ribavirin (1000 or 1200 mg/d)
Number of subjects: 1311
Study 10969302 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle absorber system
Number of subjects: 20
Study 10969302 — intervention group
Group type: EXPERIMENTAL
Intervention: NasOral system
Number of subjects: 20
Study 10969302 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation bags (disk type and duck-bill type with one-way exhalation valves)
Number of subjects: 20
Study 10969302 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation bags (duck-bill bags without exhalation valves)
Number of subjects: 20
Study 8971958 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram of 1,25(OH)2D3 administered orally for 7 days
Number of subjects: 12
Study 8971958 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 microgram of 1,25(OH)2D3 administered orally for 7 days
Number of subjects: 12
Study 8971958 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 1737537 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.075% capsaicin cream
Number of subjects: 22
Study 1737537 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 22
Study 1737537 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.075% capsaicin cream (open-label study)
Number of subjects: 22
Study 6393805 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2 g intramuscular injections at 6-hr intervals)
Number of subjects: 100
Study 6393805 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline injections)
Number of subjects: 100
Study 31596461 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (preoperative 15 mg/kg, postoperative 7.5 mg/kg two times per day for three days)
Number of subjects: 40
Study 31596461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30076807 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and midazolam
Number of subjects: 88
Study 30076807 — intervention group
Group type: COMPARATOR
Intervention: Propofol and midazolam
Number of subjects: 88
Study 28212463 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5423 (inhaled selective glucocorticoid receptor modulator)
Number of subjects: 353
Study 28212463 — intervention group
Group type: COMPARATOR
Intervention: Reference glucocorticoid receptor agonist (double the approved dose)
Number of subjects: 353
Study 28212463 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5423 and reference control
Number of subjects: 353
Study 25974071 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Number of subjects: 695
Study 25974071 — intervention group
Group type: COMPARATOR
Intervention: Usual prenatal care (control group)
Number of subjects: 695
Study 23972320 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (montelukast 4 mg and levocetirizine 2.5 mg/5 ml)
Number of subjects: 120
Study 23972320 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg
Number of subjects: 120
Study 23972320 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 2.5 mg/5 ml
Number of subjects: 120
Study 23972320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21711959 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast alone
Number of subjects: 40
Study 21711959 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine alone
Number of subjects: 40
Study 21711959 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine alone
Number of subjects: 40
Study 21711959 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and Levocetirizine combination
Number of subjects: 40
Study 21711959 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and Antihistamine combinations
Number of subjects: 40
Study 21711959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19395184 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus 6 months of HT
Number of subjects: 206
Study 19395184 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 206
Study 17000361 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise echocardiography (EE)
Number of subjects: 1916
Study 17000361 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting mitral regurgitation (MR)
Number of subjects: 1916
Study 17000361 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting MR, peak double product, peak left ventricular ejection fraction, MR worsening
Number of subjects: 1916
Study 17000361 — intervention group
Group type: EXPERIMENTAL
Intervention: MR worsening
Number of subjects: 1916
Study 15023617 — intervention group
Group type: EXPERIMENTAL
Intervention: High olive oil diet
Number of subjects: 0
Study 15023617 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate low olive oil diet
Number of subjects: 0
Study 11072942 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium butyrate (80 mmol/L, 80 mL/24 h)
Number of subjects: 20
Study 11072942 — intervention group
Group type: COMPARATOR
Intervention: Saline enemas
Number of subjects: 20
Study 11072942 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium butyrate (after switching from saline)
Number of subjects: 20
Study 8649634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous vaccination (10 micrograms once a week for 12 weeks)
Number of subjects: 25
Study 8649634 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination (40 micrograms at 0, 1, and 3 months)
Number of subjects: 25
Study 8649634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous vaccination
Number of subjects: 25
Study 1534476 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (0.1 mg of 17 beta-estradiol via dermal patches for days 1 to 21 and oral medroxyprogesterone acetate for days 11 to 21 of a 28-day cycle)
Number of subjects: 75
Study 1534476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 1534476 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Number of subjects: 75
Study 6749228 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of life stress and social isolation
Number of subjects: 2320
Study 6749228 — intervention group
Group type: COMPARATOR
Intervention: Low levels of life stress and social isolation
Number of subjects: 2320
Study 6749228 — intervention group
Group type: COMPARATOR
Intervention: Education level
Number of subjects: 2320
Study 6749228 — intervention group
Group type: EXPERIMENTAL
Intervention: Total deaths and sudden cardiac deaths
Number of subjects: 2320
Study 30429078 — intervention group
Group type: EXPERIMENTAL
Intervention: REFLEX intervention
Number of subjects: 121
Study 30429078 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (group‐wise simplified cognitive remediation training)
Number of subjects: 121
Study 29869078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (USG-TAP) block along with systemic analgesia
Number of subjects: 60
Study 29869078 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia only (Control group)
Number of subjects: 60
Study 29869078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (USG-TAP) block
Number of subjects: 60
Study 26838580 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF)
Number of subjects: 108
Study 26838580 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 108
Study 24271137 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib 1200 mg daily for 10 days
Number of subjects: 0
Study 24271137 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg for 1 day (positive control)
Number of subjects: 0
Study 24271137 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 0
Study 22752605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa
Number of subjects: 488
Study 22752605 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae
Number of subjects: 488
Study 22752605 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocardia spp.
Number of subjects: 488
Study 22752605 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcus spp.
Number of subjects: 488
Study 20674895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transvaginal aspiration and sclerotherapy with 98% ethanol
Number of subjects: 33
Study 17389552 — intervention group
Group type: EXPERIMENTAL
Intervention: PTC124 single-dose administration (3 to 200 mg/kg, specifically 50 mg/kg for pharmacokinetics)
Number of subjects: 62
Study 17389552 — intervention group
Group type: EXPERIMENTAL
Intervention: PTC124 multiple-dose administration (10 to 50 mg/kg/dose twice per day for up to 14 days)
Number of subjects: 62
Study 17389552 — intervention group
Group type: EXPERIMENTAL
Intervention: PTC124 pharmacokinetics
Number of subjects: 62
Study 15786487 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (initiated at 10 mg/day, increased to a maximum of 20 mg/day)
Number of subjects: 5453
Study 11235922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone i.m. 10 mg
Number of subjects: 117
Study 11235922 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone i.m. 2 mg
Number of subjects: 117
Study 9493770 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis EMG onset in LBP subjects
Number of subjects: 0
Study 9493770 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus abdominis, erector spinae, and oblique abdominal muscles EMG onset in LBP subjects
Number of subjects: 0
Study 9493770 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 7921531 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 alpha-gitoxin (2.5 to 15 mg, i.v. or oral)
Number of subjects: 52
Study 7921531 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 alpha-gitoxin (5 mg i.v.)
Number of subjects: 52
Study 7921531 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 alpha-gitoxin (10 mg oral)
Number of subjects: 52
Study 7921531 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 alpha-gitoxin (7.5 mg)
Number of subjects: 52
Study 7921531 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 alpha-gitoxin (various doses)
Number of subjects: 52
Study 3048090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg once daily for 10 days
Number of subjects: 565
Study 3048090 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 250 mg three times daily for 10 days
Number of subjects: 565
Study 3048090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 565
Study 3048090 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 565
Study 29193126 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg azeloprazole sodium
Number of subjects: 0
Study 29193126 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg azeloprazole sodium
Number of subjects: 0
Study 29193126 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg azeloprazole sodium
Number of subjects: 0
Study 29193126 — intervention group
Group type: COMPARATOR
Intervention: 10 mg rabeprazole sodium
Number of subjects: 0
Study 29193126 — intervention group
Group type: COMPARATOR
Intervention: 20 mg rabeprazole sodium
Number of subjects: 0
Study 29193126 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg azeloprazole sodium (before a meal)
Number of subjects: 0
Study 27921162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajust™ SIMS
Number of subjects: 58
Study 27921162 — intervention group
Group type: COMPARATOR
Intervention: Align™ transobturator tape sling
Number of subjects: 58
Study 26445155 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week physical education and games course (n = 49)
Number of subjects: 83
Study 26445155 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n = 34)
Number of subjects: 83
Study 23160722 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt drink (doogh) fortified with 500 IU vitamin D/250 mL for 12 weeks
Number of subjects: 140
Study 21245751 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Number of subjects: 0
Study 21245751 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve replacement (MVR)
Number of subjects: 0
Study 21245751 — intervention group
Group type: COMPARATOR
Intervention: Surgical revascularization alone
Number of subjects: 0
Study 18308250 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid treatment (COJEC regimen: cisplatin, vincristine, carboplatin, etoposide, cyclophosphamide)
Number of subjects: 262
Study 18308250 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (OPEC and OJEC regimens: vincristine, cisplatin, etoposide, cyclophosphamide)
Number of subjects: 262
Study 16219350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of recombinant erythropoietin (r‐EPO) and thalidomide
Number of subjects: 30
Study 16219350 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide alone (for responders of group A)
Number of subjects: 30
Study 16219350 — intervention group
Group type: COMPARATOR
Intervention: r‐EPO alone (for responders of group B)
Number of subjects: 30
Study 12650658 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole treatment
Number of subjects: 0
Study 10750335 — intervention group
Group type: EXPERIMENTAL
Intervention: H 50 mg
Number of subjects: 120
Study 10750335 — intervention group
Group type: EXPERIMENTAL
Intervention: H 100 mg
Number of subjects: 120
Study 10750335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9421123 — intervention group
Group type: EXPERIMENTAL
Intervention: OME/AMO (Omeprazole 2 x 40 mg and Amoxicillin 4 x 500 mg)
Number of subjects: 167
Study 9421123 — intervention group
Group type: EXPERIMENTAL
Intervention: OME/AMO/BSC (Omeprazole 2 x 40 mg, Amoxicillin 4 x 500 mg, and Bismuth Subcitrate 4 x 120 mg)
Number of subjects: 167